NASDAQ:TEVO

Tevogen Shares Drop After $100 Million Revenue Target; Deal Risk Eyed
·····

Tevogen Shares Drop After $100 Million Revenue Target; Deal Risk Eyed

Tevogen Bio shares fell 1.6% to $7.91 Friday after the company said potential acquisitions could add $100 million in annual revenue, though none are finalized. The stock is down 31.6% in five days and 52.2% this year. Tevogen reported no product revenue and a $5.45 million first-quarter loss, with $692,305 in cash at March’s end. The company completed a $3 million PIPE deal in May.
May 30, 2026

Stock Market Today

  • Genomic Test Could Spare Millions of Breast Cancer Patients Chemotherapy, Landmark Study Finds
    May 29, 2026, 8:16 PM EDT. A landmark study reveals that millions of breast cancer patients could safely skip chemotherapy thanks to the Prosigna genomic test, which analyses tumor genes to assess recurrence risk. The international OPTIMA trial, involving 4,429 patients, showed a 93.7% five-year cancer-free survival rate for those who avoided chemotherapy, nearly matching the 94.9% rate for those treated with it. Karen Bonham, a trial participant, described her relief upon learning she would not need chemotherapy, attributing her cancer-free status nine years post-diagnosis to the test's guidance. Experts hail the findings as gamechanging, potentially transforming breast cancer treatment by reducing unnecessary chemotherapy and its side effects, while maintaining patient safety.